Repatha is a proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor. Amgen has announced a price reduction for Repatha (evolocumab), bringing the list price of the therapy to $5,850 per year, ...

Amgen announced that as part of the company's commitment to improve patient affordability for an innovative biologic medicine for people with high cholesterol who are at risk for heart attacks and ...

Following a price cut for its Repatha SureClick auto-injector in October, Amgen Inc. (AMGN) announced on Monday it is slashing the price of all Repatha devices by 60% to $5,850 per year. Repatha, one ...

Amgen announced that all Repatha (evolocumab) devices are now available at a 60% reduced list price. This includes the pre-filled syringe, the SureClick autoinjector, and the Pushtronex device, an ...

The most commonly used delivery system, the Repatha SureClick autoinjector, was made available at the lower list price of $5,850 in October 2018. The lower priced Repatha options are identical to the ...

Amgen is making Repatha (evolocumab), an innovative biologic medicine for people with high cholesterol who are at risk for heart attacks and strokes, available at a reduced list price of $5,850 per ...